A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter
about
sameAs
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesXenobiotic, bile acid, and cholesterol transporters: function and regulation.Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participantsSeveral conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substratesImpact of OATP transporters on pharmacokinetics.The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney.Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.Genetics and the risk of neonatal hyperbilirubinemia: commentary on the article by Huang et al. on page 682.Pharmacogenetics-based new therapeutic concepts.Priorities and standards in pharmacogenetic research.Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifeneRole of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.Pharmacogenetics of chronic pain and its treatment.Role of OATP transporters in the disposition of drugs.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Overview of pharmacogenetics.Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics.SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.A genome-wide search for non-UGT1A1 markers associated with unconjugated bilirubin level reveals significant association with a polymorphic marker near a gene of the nucleoporin family.Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.A novel matrix for the short-term storage of cells: utility in drug metabolism and drug transporter studies with rat, dog and human hepatocytes.Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.Rapid genotyping of the OATP1B1 polymorphisms A388G and T521C with real-time PCR FRET assays.
P2860
Q27001267-71D96C4A-6A86-4FD1-8A71-5436B3F60B4DQ33714593-3BEAC5D9-446A-40FD-99B0-DD24D77312C3Q33776950-E5C31E47-902D-42C0-9C79-FACFAC3F8E0AQ34340098-F0D4C80B-49ED-4791-801A-A29BDD3C95D2Q34612244-1AA5C508-38B1-4061-B5F4-3D573321E795Q34613443-2E35A087-2D5C-407A-B72E-EBB868CBD508Q34777362-6EBC0685-7B13-4B62-A3DA-49B56A1D61B9Q35827696-7964493F-CF81-4F93-8981-D3D2CE111AC0Q35889227-7CD49F59-6C68-4694-A98D-8938F72B66CAQ35956177-3F8919A6-1DF3-47FA-A2CC-F979E2F40C19Q36180606-D060CB24-A1BF-4014-B0C2-01DC8894BAF2Q36334805-66F614BF-D4C4-4818-9E0B-A6A6AB3ED485Q36544966-5CDC41FE-7706-48EB-9B71-54293142AF22Q36687277-F2185A5E-2F77-4420-889E-B83E8DC87D63Q36900075-CA4343DD-7640-45D2-A628-14F83D59B798Q37074085-08096912-9C2C-4DEE-93F1-1AFEFA73F856Q37394474-CBF147BD-9A9D-4D10-800A-8B300AE5FCE1Q37680968-08EE23BA-4E9B-4CA7-8931-4E5505EB3956Q37938905-A8F3624E-749C-48A0-9E88-DE9C981C43A8Q38933314-42642A04-26B8-49D6-9096-E7A4D6AD234BQ40349386-0AEAAE78-D5E7-431C-B3D5-D4C4953A3039Q41911842-49097A55-A11D-45CC-A010-A791E8C8C5B0Q44767175-0C79D0A5-BB0D-4429-91D3-EB9018D006E9Q46378129-425C0330-142C-4A70-AF1E-EE50C5036A14Q46813708-5D261AA8-01B5-4BD0-AFE5-02B420AF3C10Q50795222-3CBA41F1-354D-4D7B-85DF-79DF8832A0F9Q54387375-047041A4-CA6C-43BB-AEAA-B11309943896Q54654987-1981BC94-A69A-4566-8478-0719E827D775
P2860
A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A naturally occurring mutation ...... hepatocyte uptake transporter
@ast
A naturally occurring mutation ...... hepatocyte uptake transporter
@en
A naturally occurring mutation ...... hepatocyte uptake transporter
@nl
type
label
A naturally occurring mutation ...... hepatocyte uptake transporter
@ast
A naturally occurring mutation ...... hepatocyte uptake transporter
@en
A naturally occurring mutation ...... hepatocyte uptake transporter
@nl
prefLabel
A naturally occurring mutation ...... hepatocyte uptake transporter
@ast
A naturally occurring mutation ...... hepatocyte uptake transporter
@en
A naturally occurring mutation ...... hepatocyte uptake transporter
@nl
P2093
P2860
P50
P3181
P356
P1476
A naturally occurring mutation ...... hepatocyte uptake transporter
@en
P2093
Andreas K Nuessler
Christoph Michalski
Dietrich Keppler
Jorg Konig
Kathrin Klein
Michel Eichelbaum
Peter Neuhaus
P2860
P304
43058-43063
P3181
P356
10.1074/JBC.M207735200
P407
P577
2002-08-23T00:00:00Z